Timothy T. Nostrant Professor of Gastroenterology and Nutrition Sciences, University Mich Medical School
Gastroenterology
Dr. William D. Chey, MD
|
|
Give Review
Dr. William D. Chey works in the field of Gastroenterology. He studied medicine at Emory University School of Medicine. Emory University School of Medicine has a rank of 23 in research and a 42 in primary care He received awards:"America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "Fellow (AGAF)", "Fellow (FACG)", "FACP", "Rome Foundation Fellow" and "Department of Internal Medicine Society of Clinical Excellence". William Chey is also a published doctor. He has 99 publication published. The most recent publication is: Timothy T. Nostrant, MD, MACG, October 20, 1947- October 2, 2015. He is registered with Medicare and accepts Medicare payments.
Publications
- Timothy T. Nostrant, MD, MACG, October 20, 1947- October 2, 2015.
- Response to Dai et al.
- Computer versus physician identification of gastroIntestinal alarm features.
- New and Emerging Treatment Options for Irritable Bowel Syndrome.
- A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease i...
- Irritable bowel Syndrome: a clinical review.
- The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden.
- Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison.
- Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with Pain and opioid-induced constipation.
- Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy?
- Naloxegol for opioid-induced constipation in patients with noncancer Pain.
- PWE-166â Is Response To Linaclotide After 4 Weeks Of Treatment Predictive Of 12-week Improvement?
- Safety and tolerability of rifaximin for the treatment of irritable bowel Syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-control...
- Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.
- An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D.
- Measuring response in the gastrointestinal tract in Systemic sclerosis.
- Breath Testing for Small Intestinal Bacterial Overgrowth: Maximizing Test Accuracy.
- Fiber and Functional GastroIntestinal Disorders.
- The Role of Food in the Functional GastroIntestinal Disorders: Introduction to a Manuscript Series.
- Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oEsophagus.
- What role does wheat play in the symptoms of irritable bowel Syndrome?
- Factors associated with symptom severity in women presenting with fecal incontinence.
- Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety.
- Agents that act luminally to treat diarrhoea and constipation.
- Current Consensus and Remaining Questions Regarding the Diagnosis and Treatment of Helicobacter pylori Infection.
- Factors associated with quality of life among women with fecal incontinence.
- Response to drs trivedi and ward.
- Image of the month: Aerophagia.
- The efficacy and safety of rifaximin for the irritable bowel syndrome: a Systematic review and meta-analysis.
- Exercise and Ibs: No Pain, No Gain.
- The Prevalence of Celiac Disease Among Patients with Non-Constipated Inflammatory Bowel Syndrome is Similar to Controls.
- Generalized Transit Delay on Wireless Motility Capsule Testing in Patients with Clinical Suspicion of Gastroparesis, Small Intestinal Dysmotility, or Slow Transit Cons...
- A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation.
- Biofeedback training for dyssynergic defecation: an approach whose time has come?
- Preface. Irritable bowel Syndrome.
- Emerging pharmacological therapies for the irritable bowel Syndrome.
- Food: the forgotten factor in the irritable bowel Syndrome.
- A clinician's guide to salvage therapy for persistent Helicobacter pylori infection.
- Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?
- St. John's wort for the treatment of irritable bowel Syndrome: reminders of the Hippocratic Oath.
- Helicobacter pylori infection.
- Acupuncture for irritable bowel Syndrome: sham or the real deal?
- Proton pump inhibitors, irritable bowel syndrome, and small Intestinal bacterial overgrowth: coincidence or Newton's third law revisited?
- The yield of colonoscopy in patients with non-constipated irritable bowel Syndrome: results from a prospective, controlled US trial.
- The impact of rotating shift work on the prevalence of irritable bowel Syndrome in nurses.
- Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies.
- The American College of Gastroenterology irritable bowel syndrome monograph: translating Systematic review data to clinical practice.
- Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls.
- ACP Journal Club. Psyllium increased symptom relief in patients with the irritable bowel Syndrome more than bran or placebo.
- Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
- Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS.
- Psychometric evaluation of patient-reported outcomes in irritable bowel Syndrome randomized controlled trials: a Rome Foundation report.
- Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?
- Developing valid and reliable health utilities in irritable bowel Syndrome: results from the IBS PROOF Cohort.
- The FODMAP diet for irritable bowel Syndrome: food fad or roadmap to a new treatment paradigm?
- Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis.
- Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation.
- Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis.
- The utility of probiotics in the treatment of irritable bowel syndrome: a Systematic review.
- Investigation of Colonic and Whole Gut Transit with Wireless Motility Capsule and Radioopaque Markers in Constipation.
- Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort?
- Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel Syndrome.
- Bacterial overgrowth and irritable bowel Syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?
- Methylnaltrexone: a new treatment for an old problem.
- Successful physical therapy for constipation related to puborectalis dyssynergia improves symptom severity and quality of life.
- Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what's next?
- Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials.
- Differences in intraGastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of Gastric retention.
- Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
- Breath tests for gastrointestinal Disease: the real deal or just a lot of hot air?
- Successful treatment of common variable immunodeficiency disorder-associated diarrhea with budesonide: a case report.
- Irritable bowel Syndrome: update on colonic neuromuscular dysfunction and treatment.
- Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveil...
- Functional bowel disorders.
- Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
- Clinical predictors of Barrett's Esophagus length.
- Peptic ulcer Disease in patients with chronic liver Disease: looking beyond bugs and drugs.
- Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey.
- Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel Disease.
- A clinician's guide to managing Helicobacter pylori infection.
- Helicobacter pylori eradication had no effect on heartburn or gastroEsophageal reflux in H pylori infection.
- Clostridial aortitis and colon Cancer.
- Endoscopy-negative reflux Disease: concepts and clinical practice.
- Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.
- Erosive Esophagitis and NERD: Can we really classify patients with heartburn by endoscopic findings?
- Tegaserod does not alter fasting or meal-induced Biliary tract motility.
- Ulcerative colitis associated Enteritis: is ulcerative colitis always confined to the colon?
- Nausea and vomiting.
- Advances in the management of irritable bowel Syndrome.
- An evidence-based approach to clinical practice guidelines: diagnosis and treatment of irritable bowel Syndrome.
- Review: tegaserod or alosetron is effective for the irritable bowel Syndrome.
- Number of responses on a review of Systems questionnaire predicts the diagnosis of functional gastrointestinal disorders.
- Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary Achalasia.
- Tegaserod and other serotonergic agents: what is the evidence?
- The utility of diagnostic tests in irritable bowel syndrome patients: a Systematic review.
- Utility of the Rome I and Rome II criteria for irritable bowel Syndrome in U.S. women.
- Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways.
- Uninvestigated Dyspepsia.
Schools
Emory University School Of Medicine
Emory University Hospital
Emory University School Of Med
University Mich Hosps
Procedures Preformed
- Anoscopy
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Manometry
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Golden Rule
- Health Alliance
- Preferred PPO
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Paramount
- PHP-Physicians Health Plan
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Fellow (AGAF)
- Fellow (FACG)
- FACP
- Rome Foundation Fellow
- Department of Internal Medicine Society of Clinical Excellence
Education
-
University of Michigan Hospitals and Health Centers -
Emory University -
Emory University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1487736906 | |
| NPPES Provider LastName | CHEY | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 481095362 | |
| NPPES Provider State | MI | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 338.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487736906 |
| Last Name Of The Provider | CHEY |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
|
Dr. Eugenius S. Ang, MD |
|
|
Dr. Michael D. Rice, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amit Singal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leslie B. Aldrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Saad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameer D. Saini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Swati G. Patel, MD |
|
|
Dr. Rebecca W. Vandyke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aarti Y. Oza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mari A. Rivera, MD |